DURECTNASDAQ: DRRX

- Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design - Single Phase 3 trial designed to enroll 200 U.S. patients with a 90-day survival primary endpoint; topline results expected within two years of trial initiation  - Protocol for Phase 3 trial builds on data from the AHFIRM Phase 2b trial; 30 mg and 90 mg doses of larsucosterol reduced 90-day mortality in U.S. patients by 57% and 58%, respectively, compared with placebo CUPERTINO, Calif. , Sept. 25, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today provided details on the design of its upcoming registrational Phase 3 trial which will evaluate larsucosterol for the treatment of patients with severe alcohol-associated hepatitis (AH).

CUPERTINO, Calif. , Sept. 4, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced management's participation in the H.C.

Durect (DRRX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.46 per share a year ago.

-         FDA Granted Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis -         Held Type B Meeting with FDA to Discuss Phase 3 Clinical Trial Design -         Seeking to Initiate Phase 3 Trial in 2024 with Topline Results Expected in 2H 2026 -         Webcast of Earnings Call Today, August 13th at 4:30 p.m. ET CUPERTINO, Calif.

CUPERTINO, Calif. , Aug. 7, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its second quarter financial results on Tuesday, August 13, 2024.

Here is how Durect (DRRX) and Elevance Health (ELV) have performed compared to their sector so far this year.

DURECT Corporation's Q1 2024 Earnings Conference Call is scheduled for May 13, 2024 at 4:30 PM ET, with CFO Timothy M. Papp and James E. participating.

Durect (DRRX) reported a quarterly loss of $0.25 per share, which was slightly higher than the Zacks Consensus Estimate of a loss of $0.21. This is an improvement from the loss of $0.52 per share in the same quarter last year.

Durect (DRRX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.46 per share a year ago.